USPTO serial 99912680
KNOA PHARMACEUTICALS
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- PAQUIN, SAMUEL ROBERT
- Law office
- TMEG LAW OFFICE 101
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with KNOA PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Stamford, CT, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Fara S. Sunderji
Fara S. Sunderji Dorsey & Whitney LLP1301 Avenue of the Americas, 13th FloorNew York, NY 10019United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists | ACTIVE | — |
| 042 | Pharmaceutical research and development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 4, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 4, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 2, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 26, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 29, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 29, 2026 | NWAP | NEW APPLICATION ENTERED | — |